Ramucirumab + Pembrolizumab
Phase 2ActiveDevelopment Stage
Recurrent Head and Neck Cancer
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
Oct 27, 2023 → Jun 30, 2030
About Ramucirumab + Pembrolizumab
Ramucirumab + Pembrolizumab is a phase 2 stage product being developed by Eli Lilly for Recurrent Head and Neck Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05980000. Target conditions include Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Head and Neck Cancer were approved
Hype Score Breakdown
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05980000 | Phase 2 | Active |
| NCT03650764 | Phase 1/2 | Active |
| NCT02443324 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Head and Neck Cancer